TetraGenetics, Inc.
Have updates for this profile? Please contribute data
= Subscriber Access Only
You are viewing a preview of this profile. Request a Preqin Pro demo for full access to all profiles and underlying data.
With Preqin Pro, you gain an unobstructed view of all alternative asset class activity across institutional investors, fund managers, funds, portfolio companies, deals, exits, and service providers.
TetraGenetics, Inc. - overview
Established
2004
Location
-, MA, US
Primary Industry
Biotechnology
About
TetraGenetics, Inc. is a biotechnology firm specializing in the development of antibody-based medicines, aimed at addressing complex medical conditions through innovative therapeutic solutions. Founded in 2004 and headquartered in Arlington, US, TetraGenetics, Inc. focuses on the creation of advanced antibody medicines.
The company was acquired by AbCellera Biologics Inc. in September 2021. Doug Kahn serves as the CEO, leading the organization through its strategic developments. TetraGenetics offers a range of products centered around innovative antibody therapeutics.
Their portfolio includes monoclonal antibodies targeting medical conditions, enhancing treatment efficacy for various diseases. The company collaborates with pharmaceutical and biotechnology partners worldwide to advance numerous antibody drug programs, primarily in North America and Europe. TetraGenetics derives its revenue from partnerships with pharmaceutical and biotechnology companies through research and development agreements, milestone payments, and royalties from successful product commercialization. The financial model includes initial payments upon starting partnerships and subsequent payments based on achieving specific development milestones.
TetraGenetics plans to leverage the recent funding from the acquisition to further develop new antibody products and expand its market reach. The company is targeting broader international markets in Asia and Europe, with initiatives aimed for implementation by late 2023. The funding will support research and development efforts to enhance existing products and introduce new therapeutic solutions.
Current Investors
JDRF T1D Fund, AbCellera Biologics Inc., University of Minnesota
Primary Industry
Biotechnology
Sub Industries
Biopharmaceuticals, Pharmaceutical Research & Development
Website
www.tetragenetics.com
Verticals
HealthTech
Company Stage
Add-on
Total Amount Raised
Subscriber access only
TetraGenetics, Inc. - employee data
Time to go Pro
Get Preqin Pro for unrestricted access to 600,000+ detailed profiles on fund managers, investors, funds, companies, and other alternative asset players. Unlock exclusive data on future plans, company financials, fundraising history, track records, and more.